OnKure Therapeutics logo

OnKure Therapeutics

OnKure is engaged in the discovery and development of epigenetic therapies for the treatment of cancer that include selective inhibitors of histone deacetylases (HDACs). In preclinical models of both hematological and solid tumor cancers, our lead candidate, ONK-179, significantly and safely reduces the growth rate of tumors when dosed by itself or in combination with other targeted therapies.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://onkuretherapeutics.com
Founded2011
Disease Focus
Development Stage
STOCK CODENon Listed
Address
1067 S. Hover Street Unit E, PMB # 204, CO, 80501
Longmont
United States
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]